Madrigal Pharmaceuticals

Yahoo Finance • last month

Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now?

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) ranks among the best guru stocks to buy now. Due to the plethora of investment o... Full story

Yahoo Finance • 5 months ago

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trad... Full story

Yahoo Finance • 6 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

Madrigal Pharmaceuticals, Inc. CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prio... Full story

Yahoo Finance • 9 months ago

15 Best Strong Buy Stocks To Invest In

In this piece, we will take a look at the 15 best strong buy stocks to invest in. If you want to skip our overview of analyst ratings and the finance industry, then you can take a look at the 5 Best Strong Buy Stocks To Invest In. The fin... Full story

Yahoo Finance • 10 months ago

3 Stocks That Could Be Monster Winners in 2024

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task. Three Motley Fool contributors think they've identified stocks that could be... Full story

Yahoo Finance • 11 months ago

11 Stocks Insiders and Billionaires Are Crazy About

In this article, we will take a detailed look at the11 Stocks Insiders and Billionaires Are Crazy About. For a quick overview of such stocks, read our article 5 Stocks Insiders and Billionaires Are Crazy About. In his famous book titled O... Full story

Yahoo Finance • 11 months ago

Insider Sell Alert: Senior VP Robert Waltermire Sells 3,800 Shares of Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has recently witnessed a significant insider sell that has caught the attention of investors and market analysts. On December 13, 2023, Senior Vice President and Chief Pharmaceutical Development O... Full story

Yahoo Finance • 11 months ago

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the c... Full story

Yahoo Finance • 11 months ago

11 Best Upside Stocks To Buy Right Now

In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has alw... Full story

Yahoo Finance • 12 months ago

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronal... Full story

Yahoo Finance • 12 months ago

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

Data to be featured in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®Analyses from comprehensive set of noninvasive tests used in MAESTRO-NASH provide new insights on strategies to i... Full story

Yahoo Finance • 12 months ago

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carol... Full story

Yahoo Finance • 12 months ago

Madrigal Pharmaceuticals Inc (MDGL) Reports Third Quarter 2023 Financial Results

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) reported cash, cash equivalents and marketable securities of $232.4 million as of September 30, 2023. Operating expenses for the nine-month period ended September 30, 2023, were $263.3 million, co... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

Priority Review of resmetirom new drug application underway in the U.S. Bill Sibold appointed Chief Executive Officer of Madrigal in September 2023$500 million financing provides Madrigal with funds to support a potential first-to-market l... Full story

Yahoo Finance • last year

12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massiv... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its manag... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the pric... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Announces Proposed Public Offering

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the... Full story

Yahoo Finance • last year

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

CONSHOHOCKEN, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced the completion o... Full story